Charlene Hoffman Snyder.

Richard J. Caselli, M.D ., Amylou C. Dueck, Ph.D., David Osborne, Ph.D., Marwan N. Sabbagh, M.D., Donald J. Connor, Ph.D., Geoffrey L. Ahern, M.D., Ph.D., Leslie C. Baxter, Ph.D., Steven Z. Rapcsak, M.D., Jiong Shi, M.D., Bryan K. Woodruff, M.D., Dona E.C. Locke, Ph.D., Charlene Hoffman Snyder, C.N.P., Gene E. Alexander, Ph.D., Rosa Rademakers, Ph.D., and Eric M. Reiman, M.D.1-3 Although memory space loss is the earliest cognitive modification in Alzheimer’s disease,4-9 distinguishing early disease from normal aging could be difficult.14-16 Such decline correlates with reduced cerebral metabolism just as much as 5 to 10 years before the onset of cognitive symptoms.17 The idea of transition from normal aging to Alzheimer’s disease has been sought in population-based studies, but cross-sectional designs are limited by demographic differences among subjects that influence neuropsychological test results.

The dexamethasone suspension contains generic dexamethasone phosphate injection alternative blended with Ora-Plus and Ora-Sweet . The placebo contains Ora-Plus and Ora-Sweet. The research nurse administered all drugs in the emergency section and trained parents how to administer the oral medication at home. The treating physician in the emergency department was allowed to offer cointerventions after 90 minutes and individually motivated whether to admit or discharge the infant. Randomization The computer-generated randomization sequence, stratified by center, used randomized permuted blocks of 8 and 12.